{"meshTagsMajor":["Genes, abl","Mutation"],"meshTags":["Protein Kinase Inhibitors","Genes, abl","Piperazines","Leukemia, Myelogenous, Chronic, BCR-ABL Positive","Humans","Female","Pyrimidines","Mutation","Thiazoles","Male","Dasatinib","Benzamides","Imatinib Mesylate"],"meshMinor":["Protein Kinase Inhibitors","Piperazines","Leukemia, Myelogenous, Chronic, BCR-ABL Positive","Humans","Female","Pyrimidines","Thiazoles","Male","Dasatinib","Benzamides","Imatinib Mesylate"],"genes":["tyrosine kinase"],"publicationTypes":["Comment","Editorial"],"title":"[Chronic myeloid leukemia and resistance to tyrosine kinase inhibitors: ABL mutations, much ado about nothing?].","pubmedId":"23462544"}